Fig. 1From: Feasibility study of docetaxel plus bevacizumab as first line therapy for elderly patients with advanced non-small-cell lung cancer: Thoracic Oncology Research Group (TORG) 1014Kaplan-Meier curves for progression-free survival a and overall survival bBack to article page